CSPC Pharmaceutical Group (HK:1093) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CSPC Pharmaceutical Group Limited has announced that their novel antibody drug conjugate, CPO301, received Fast Track Designation from the US FDA for treating a specific form of lung cancer. This marks the second such designation for CPO301, aiming to accelerate the drug’s development in the US market. The medication has shown promise in Phase I trials, offering potential new treatment options for patients with recurrent or metastatic squamous non-small cell lung cancer.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.